Backed by a select group of new and existing mission-aligned investors, the round validates Amaros' mission to transform fragmented clinical data into real-time, actionable intelligence for eye care.

Amaros is redefining the future of ophthalmic care through deep tech innovation. Its flagship platform, EvidenceEngine, integrates diverse datasets - including electronic medical records, imaging, genomics, provider notes and claims - into structured information that provides real-time insights. Designed with a human-centric mindset, the platform empowers stakeholders across the eye care continuum to make smarter decisions, faster. From accelerating clinical trials to identifying unmet needs and optimizing treatment strategies, Amaros delivers the intelligence that modern ophthalmology demands.